Axatilimab is under clinical development by Syndax Pharmaceuticals and currently in Phase II for Idiopathic Pulmonary Fibrosis. According to GlobalData, Phase II drugs for Idiopathic Pulmonary Fibrosis have a 35% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Axatilimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Axatilimab overview
Axatilimab (SNDX-6352) is under development for the treatment of graft versus host disease, solid tumours including intrahepatic cholangiocarcinoma, human epidermal growth factor receptor 2 negative breast cancer, relapsed and refractory Hodgkin Lymphoma and idiopathic pulmonary fibrosis. It is administered intravenously as solution for infusion. The drug candidate is a humanized IgG4 monoclonal antibody targeting colony stimulating factor 1 receptor (CSF1R). It was under development for Coronavirus disease 2019 (COVID-19).
Syndax Pharmaceuticals overview
Syndax Pharmaceuticals (Syndax) is a biopharmaceutical company that discovers, develops and commercializes therapies for multiple cancer indications. The company’s pipeline products include AUGMENT-101-2A for the treatment of R/R KMT2Ar acute lymphoblastic leukemia (ALL), AUGMENT-101-2B treats R/R KMT2Am acute myeloid eukemia (AML); AUGMENT-101-2C for R/R NPM1m Acute Myeloid Leukemia (AML); AUGMENT-102 targets R/R KMT2Ar and NPM1m acute leukemias; BEAT-AML for the treatment of Frontline KMT2Ar and NPM1m Acute Myeloid Leukemia (AML); INTERCEPT for MRD- progression in KMT2Ar and NPM1m acute myeloid leukemia (AML); Colorectal Cancer targets newly diagnosed NPM1m or KMT2Ar acute leukemias; AGAVE-201 treats chronic graft-versus-host disease (GVHD); Idiopathic Pulmonary Fibrosis for idiopathic pulmonary fibrosis. Syndax is headquartered in Waltham, Massachusetts, the US.
For a complete picture of Axatilimab’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
